Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease
- PMID: 19779400
Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease
Abstract
The Advisory Committee on Immunization Practices (ACIP) recommends quadrivalent meningococcal conjugate vaccine, (MCV4) (Menactra, Sanofi Pasteur, Swiftwater, Pennsylvania) for all persons aged 11-18 years and for persons aged 2-55 years at increased risk for meningococcal disease. MCV4 is licensed as a single dose. Because of the high risk for meningococcal disease among certain groups and limited data on duration of protection, at its June 2009 meeting ACIP recommended that persons previously vaccinated with either MCV4 or MPSV4 (Menomune, Sanofi Pasteur) who are at prolonged increased risk for meningococcal disease should be revaccinated with MCV4. Persons who previously were vaccinated at age >or=7 years and are at prolonged increased risk should be revaccinated 5 years after their previous meningococcal vaccine, and persons who previously were vaccinated at ages 2-6 years and are at prolonged increased risk should be revaccinated 3 years after their previous meningococcal vaccine. Persons at prolonged increased risk for meningococcal disease include 1) persons with increased susceptibility such as persistent complement component deficiencies (e.g., C3, properdin, Factor D, and late complement component deficiencies), 2) persons with anatomic or functional asplenia, and 3) persons who have prolonged exposure (e.g., microbiologists routinely working with Neisseria meningitidis, or travelers to or residents of countries where meningococcal disease is hyperendemic or epidemic). This report provides the rationale for the new recommendation and updates and replaces previous recommendations for revaccination with MCV4.
Similar articles
-
Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep. 2013 Mar 22;62(RR-2):1-28. MMWR Recomm Rep. 2013. PMID: 23515099
-
Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep. 2005 May 27;54(RR-7):1-21. MMWR Recomm Rep. 2005. PMID: 15917737
-
Updated recommendations for use of meningococcal conjugate vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010.MMWR Morb Mortal Wkly Rep. 2011 Jan 28;60(3):72-6. MMWR Morb Mortal Wkly Rep. 2011. PMID: 21270745
-
Update on prevention of meningococcal disease: focus on tetravalent meningococcal conjugate vaccine.Ann Pharmacother. 2006 Apr;40(4):666-73. doi: 10.1345/aph.1G486. Epub 2006 Mar 7. Ann Pharmacother. 2006. PMID: 16595570 Review.
-
Use of meningococcal vaccines in the United States.Pediatr Infect Dis J. 2007 May;26(5):371-6. doi: 10.1097/01.inf.0000259996.95965.ef. Pediatr Infect Dis J. 2007. PMID: 17468644 Review.
Cited by
-
Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.MMWR Recomm Rep. 2020 Sep 25;69(9):1-41. doi: 10.15585/mmwr.rr6909a1. MMWR Recomm Rep. 2020. PMID: 33417592 Free PMC article.
-
UPDATE ON THE USE OF QUADRIVALENT CONJUGATE MENINGOCOCCAL VACCINES: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).Can Commun Dis Rep. 2013 Jan 2;39(ACS-1):1-40. doi: 10.14745/ccdr.v39i00a01. eCollection 2013 Jan 2. Can Commun Dis Rep. 2013. PMID: 31697281 Free PMC article. No abstract available.
-
Immunogenicity of a Booster Dose of Quadrivalent Meningococcal Conjugate Vaccine in Previously Immunized HIV-Infected Children and Youth.J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):e69-e74. doi: 10.1093/jpids/piw094. J Pediatric Infect Dis Soc. 2017. PMID: 28339668 Free PMC article. Clinical Trial.
-
Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid).Hum Vaccin Immunother. 2016 Jul 2;12(7):1777-94. doi: 10.1080/21645515.2016.1150396. Epub 2016 May 2. Hum Vaccin Immunother. 2016. PMID: 27135390 Free PMC article. Review.
-
Travel advice for the immunocompromised traveler: prophylaxis, vaccination, and other preventive measures.Ther Clin Risk Manag. 2015 Feb 12;11:217-28. doi: 10.2147/TCRM.S52008. eCollection 2015. Ther Clin Risk Manag. 2015. PMID: 25709464 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous